From: Gottschalk, Laura

Sent: Monday, July 26, 2021 2:06 PM

To: Harkins Tull, Elisa < Elisa. Harkins Tull@pfizer.com>

Cc: Naik, Ramachandra < Ramachandra. Naik@fda.hhs.gov>; Smith, Michael (CBER)

 $<\!Michael.Smith 2@fda.hhs.gov>; Devlin, Carmel M <\!Carmel.Devlin@pfizer.com>; Aghajani Memar, Nedabeta Aghajani Memar,$

<Neda.AghajaniMemar@pfizer.com>

Subject: STN 125742/0: IR RE disposition of participants in safety populations who experienced

pregnancy

Dear Ms. Harkins,

The review team has comments for you regarding the disposition of participants in safety populations who experienced pregnancy. Please complete and submit the following table to your BLA by this Friday, July 30, 2021:

Table X: Disposition of Participants 16 Years of age and Older, Safety Populations who Experienced Pregnancy through 13 March 2021

	BNT162b2 (N=)	Placebo (N=)	Total (N=)
Treatment Group	n (%)	n (%)	n (%)
Total number of			
pregnancies			
Withdrawal from study			_
due to pregnancy			
Timing of pregnancy			
Completed 1 dose			
Completed 2 doses			
Completed 3 doses			
Completed 4 doses			
Spontaneous Abortions			
Elective Abortions			
Miscarriage			_
Fetal demise			
Birth outcomes known			
Unknown pregnancy			
outcomes			
Ongoing pregnancy			
Major birth defect		<u> </u>	

Please provide the timing of the last dose (BNT162b2), relative to LMP: study vaccination occurred prior to LMP, within 30 days of LMP and >30 days after LMP. This may be expressed as a percentage of total pregnancies.

Please acknowledge receipt of this message and let me know if you have any questions.

Best, Laura

Laura Gottschalk, PhD

Regulatory Project Manager/Primary Reviewer

Center for Biologics Evaluation and Research Office of Vaccines Research and Review U.S. Food and Drug Administration Tel: 301-796-0798 laura.gottschalk@fda.hhs.gov











THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.